Terms: = Ovarian cancer AND LMNA, EMD2, 4000, ENSG00000160789, LGMD1B, LDP1, PRO1, LMNC, FPLD, CDDC, HGPS, P02545, LFP, IDC, CMD1A, CDCD1, LMN1, CMT2B1, FPL AND Treatment
27 results:
1. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract] [Full Text] [Related]
2. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients.
Esmaeilian Y; Hela F; Bildik G; Akin N; İltumur E; Yusufoglu S; Yildiz CS; Keles İ; Vatansever D; Taskiran C; Yakin K; Oktem O
Hum Reprod; 2023 Jan; 38(1):113-124. PubMed ID: 36367834
[TBL] [Abstract] [Full Text] [Related]
3. Collection of cancer Patient Reported Outcome Measures (PROMS) to link with primary and secondary electronic care records to understand and improve long term cancer outcomes: A protocol paper.
Stamp E; Clarke G; Wright P; Velikova G; Crossfield SSR; Zucker K; McInerney C; Bojke C; Martin A; Baxter P; Woroncow B; Wilson D; Warrington L; Absolom K; Burke D; Stables GI; Mitra A; Hutson R; Glaser AW; Hall G
PLoS One; 2022; 17(4):e0266804. PubMed ID: 35427401
[TBL] [Abstract] [Full Text] [Related]
4. Suppression of DNA Polymerase β Activity Is Synthetically Lethal in BRCA1-Deficient Cells.
Yuhas SC; Mishra A; DeWeese TL; Greenberg MM
ACS Chem Biol; 2021 Aug; 16(8):1339-1343. PubMed ID: 34240844
[TBL] [Abstract] [Full Text] [Related]
5. Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project.
De Gregorio A; Nagel G; Möller P; Rempen A; Schlicht E; Fritz S; Flock F; Kühn T; Thiel F; Felberbaum R; Ebner F; De Gregorio N; Friedl TWP; Wiesmüller L; Kuhn P; Schmitt M; Janni W; Rothenbacher D; Huober J
Arch Gynecol Obstet; 2020 Jan; 301(1):273-281. PubMed ID: 31781887
[TBL] [Abstract] [Full Text] [Related]
6. Dual-drug loaded micelle for combinatorial therapy targeting HIF and mTOR signaling pathways for ovarian cancer treatment.
Doddapaneni BS; Al-Fatease AM; Rao DA; Alani AWG
J Control Release; 2019 Aug; 307():272-281. PubMed ID: 31260753
[TBL] [Abstract] [Full Text] [Related]
7. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract] [Full Text] [Related]
8. Presymptomatic Identification of cancers in Pregnant Women During Noninvasive Prenatal Testing.
Amant F; Verheecke M; Wlodarska I; Dehaspe L; Brady P; Brison N; Van Den Bogaert K; Dierickx D; Vandecaveye V; Tousseyn T; Moerman P; Vanderstichele A; Vergote I; Neven P; Berteloot P; Putseys K; Danneels L; Vandenberghe P; Legius E; Vermeesch JR
JAMA Oncol; 2015 Sep; 1(6):814-9. PubMed ID: 26355862
[TBL] [Abstract] [Full Text] [Related]
9. Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.
Ingersoll SB; Ahmad S; McGann HC; Banks RK; Stavitzski NM; Srivastava M; Ali G; Finkler NJ; Edwards JR; Holloway RW
Mol Cell Biochem; 2015 Sep; 407(1-2):281-7. PubMed ID: 26048718
[TBL] [Abstract] [Full Text] [Related]
10. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract] [Full Text] [Related]
11. Retinoids and their biological effects against cancer.
Alizadeh F; Bolhassani A; Khavari A; Bathaie SZ; Naji T; Bidgoli SA
Int Immunopharmacol; 2014 Jan; 18(1):43-9. PubMed ID: 24239628
[TBL] [Abstract] [Full Text] [Related]
12. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
[TBL] [Abstract] [Full Text] [Related]
13. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Rocconi RP; Case AS; Straughn JM; Estes JM; Partridge EE
Cancer; 2006 Aug; 107(3):536-43. PubMed ID: 16804928
[TBL] [Abstract] [Full Text] [Related]
14. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and treatment of cancer New Drug Development Group.
Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588
[TBL] [Abstract] [Full Text] [Related]
15. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Copeland LJ; Bookman M; Trimble E;
Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S1-7. PubMed ID: 12927999
[TBL] [Abstract] [Full Text] [Related]
16. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells.
Grimshaw MJ; Naylor S; Balkwill FR
Mol Cancer Ther; 2002 Dec; 1(14):1273-81. PubMed ID: 12516960
[TBL] [Abstract] [Full Text] [Related]
17. The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.
Topuz E; Eralp Y; Saip P; Aydiner A; Taş F; Saliho Y; Salihoğlu Y; Berkman S; Bengisu E
Eur J Gynaecol Oncol; 2001; 22(1):70-3. PubMed ID: 11321501
[TBL] [Abstract] [Full Text] [Related]
18. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease.
Williams RS; Littell RD; Mendenhall NP
Cancer; 1999 Nov; 86(10):2138-42. PubMed ID: 10570443
[TBL] [Abstract] [Full Text] [Related]
19. Limited-field radiotherapy as salvage treatment of localized persistent or recurrent epithelial ovarian cancer.
Davidson SA; Rubin SC; Mychalczak B; Saigo PE; Lewis JL; Chapman D; Hoskins WJ
Gynecol Oncol; 1993 Dec; 51(3):349-54. PubMed ID: 8112644
[TBL] [Abstract] [Full Text] [Related]
20. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma.
Lennon VA; Sas DF; Busk MF; Scheithauer B; Malagelada JR; Camilleri M; Miller LJ
Gastroenterology; 1991 Jan; 100(1):137-42. PubMed ID: 1845756
[TBL] [Abstract] [Full Text] [Related]
[Next]
